01.02.24
Biora Therapeutics Inc., a biotech company focused on creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, reported that its BioJet Systemic Oral Delivery Platform has met key performance milestones as part of its research collaboration with AstraZeneca. The BioJet platform is designed to use needle-free, liquid jet injection to deliver drug into the small intestine for systemic absorption.
The BioJet platform uses an ingestible device designed to transit through the digestive system and activate in the small intestine, where liquid jets deliver drug directly into the small intestine for uptake into systemic circulation. Approximately the size of a multivitamin, the BioJet device is designed to autonomously deliver a wide range of large molecules, such as proteins, peptides, and nucleic acids, in liquid formulation at multi-milligram doses, without requiring complex reformulation.
“In a preclinical study, we assessed the bioavailability of our collaborator’s molecule when delivered via our BioJet device in a porcine model, with comparison to subcutaneous administration,” said Sharat Singh, head of research at Biora Therapeutics. “BioJet devices were administered endoscopically, which is typical in a porcine model, and released for autonomous activation. We are encouraged by the results, which met our performance targets of greater than 25% bioavailability compared to subcutaneous delivery, and less than 50% coefficient of variation.”
The BioJet platform uses an ingestible device designed to transit through the digestive system and activate in the small intestine, where liquid jets deliver drug directly into the small intestine for uptake into systemic circulation. Approximately the size of a multivitamin, the BioJet device is designed to autonomously deliver a wide range of large molecules, such as proteins, peptides, and nucleic acids, in liquid formulation at multi-milligram doses, without requiring complex reformulation.
“In a preclinical study, we assessed the bioavailability of our collaborator’s molecule when delivered via our BioJet device in a porcine model, with comparison to subcutaneous administration,” said Sharat Singh, head of research at Biora Therapeutics. “BioJet devices were administered endoscopically, which is typical in a porcine model, and released for autonomous activation. We are encouraged by the results, which met our performance targets of greater than 25% bioavailability compared to subcutaneous delivery, and less than 50% coefficient of variation.”